NantKwest (NK) IPO Prices at $25, Above Expected Range

NantKwest (NASDAQ: NK) announced today the pricing of its initial public offering of 8,288,000 shares of its common stock at a price to the public of $25.00 per share, above the expected $20-$23 range. Shares are expected to begin trading today on the NASDAQ under the symbol "NK." Shares are initially expected to open at approximately 10:25AM ET.

BofA Merrill Lynch, Citigroup Global Markets Inc., Jefferies LLC and Piper Jaffray are acting as joint book-running managers for the offering, and MLV & Co. LLC is acting as co-manager.

NantKwest is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.

You May Also Be Interested In

• SK hynix files for Nasdaq IPO under ticker symbol SKHY
• Radoff-JEC Group pushes for board seats at Seer amid proxy fight
• Absci, FuelCell Energy surge premarket; Cerebras, FedEx tumble